
    
      To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from
      moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 weeks
      open label or double blind extension

      Study Hypotheses:

      Null hypothesis: No difference between pramipexole and placebo in RLSRS total score from
      baseline and no difference in the CGI-I responder rates at the end of the 6 weeks
      double-blind treatment.

      Comparison(s):

      Pramipexole vs. Placebo
    
  